SUPN · Supernus Pharmaceuticals, Inc.
$43.24
-2.77 (-6.01%)
At close · Aug 4
Market Cap
$2.67B
Shares
58.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$46.00
Open$50.45
Day$44.17–52.50
52W$34.64–59.68
Avg vol 30d915K
Short int4.9M · 8.3% float · 5.1d
Short vol41%
Last earningsJul 22, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Oct 15, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 15.9 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
−1%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
45%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−10%
trailing
YTD return
−7%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $46 › 200d $49 — 200d above 50d
Institutional flow
Distributing
100 of 328 funds reported for Jun 30 · net -145.2K sh shares · +10 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.35% of float · ▼ -32.1% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
328 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
EPS growth
−152%
Y/Y
Free cash flow
$46.0M
Balance sheet
$250.8M
net debt
Quant / Vol
risk profile
Volatility
37%
annualized · 1-yr
Max drawdown
−24%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Total revenues
· full year 2026
Maintained
$840M – $870M
prior FY $718.95M
midpoint +18.9% Y/Y
Guided vs delivered
· last 2 settled
Total revenues
full year 2025
guided $600M – $630M
$718.95M
Beat +16.9%
Combined net sales of Trokendi XR and Oxtellar XR
2024
guided $135M – $145M
$661.82M
Beat +372.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
45%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $46 › 200d $49 — 200d above 50d
Institutional flow
Distributing
100 of 328 funds reported for Jun 30 · net -145.2K sh shares · +10 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.35% of float · ▼ -32.1% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
328 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $35
Now $46 · 45%
52-wk high $60
vs 200-day avg -6%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total revenues from commercial products (Non-GAAP) non-GAAP | $379.5M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Total IQVIA prescriptions for Qelbree | 254,824 | Q1 2026 | — |
|
|
|||
| Adjusted operating earnings (non-GAAP) non-GAAP | $158.7M | twelve months ended December 31, 2025 | — |
| Combined revenues of the Company's four growth products | $521.8M | Full Year 2025 | — |
| ONAPGO enrollment forms submitted since launch | 1,800 | since launch through Q4 2025 | — |
| ONAPGO prescribers since launch | 540 | since launch through Q4 2025 | — |
| Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP) non-GAAP | $635.9M | Year Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SUPN
this stock
Supernus Pharmaceuticals, Inc.
|
$2.67B | -7.4% | -3.9% | — | 8.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.75B | +8.0% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.10B | +3.7% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.16B | -3.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SUPN | -2.1% | -2.6% | -10.3% | +3.1% | -7.4% |
| SPY | +2.5% | +0.9% | +9.2% | +1.4% | +11.1% |
| vs SPY | -4.6% | -3.5% | -19.5% | +1.7% | -18.6% |
Key facts
CIK
1356576
CUSIP
868459108
13F (30d)
89 filings
88 filers
Visit website
Investor relations